Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Other Working Capital Changes: 2011-2025

Historic Other Working Capital Changes for Northwest Biotherapeutics (NWBO) over the last 8 years, with Sep 2025 value amounting to -$8,000.

  • Northwest Biotherapeutics' Other Working Capital Changes fell 144.44% to -$8,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$11,000, marking a year-over-year decrease of 104.76%. This contributed to the annual value of $64,000 for FY2024, which is 73.55% down from last year.
  • According to the latest figures from Q3 2025, Northwest Biotherapeutics' Other Working Capital Changes is -$8,000, which was down 113.79% from $58,000 recorded in Q2 2025.
  • Northwest Biotherapeutics' Other Working Capital Changes' 5-year high stood at $125,000 during Q4 2023, with a 5-year trough of -$42,000 in Q2 2021.
  • For the 3-year period, Northwest Biotherapeutics' Other Working Capital Changes averaged around $30,636, with its median value being $40,000 (2023).
  • Its Other Working Capital Changes has fluctuated over the past 5 years, first crashed by 171.19% in 2021, then surged by 275.00% in 2022.
  • Quarterly analysis of 5 years shows Northwest Biotherapeutics' Other Working Capital Changes stood at $27,000 in 2021, then spiked by 37.04% to $37,000 in 2022, then spiked by 237.84% to $125,000 in 2023, then slumped by 133.60% to -$42,000 in 2024, then tumbled by 144.44% to -$8,000 in 2025.
  • Its last three reported values are -$8,000 in Q3 2025, $58,000 for Q2 2025, and -$19,000 during Q1 2025.